Text Size

Validation of RDQ Questionnaire

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00291746
First received: February 14, 2006
Last updated: March 11, 2009
Last verified: March 2009
History of Changes
  Purpose

The primary objective of this study is to determine the accuracy of the Reflux Disease Questionnaire (RDQ) as a diagnostic test for gastroesophageal reflux disease. Symptom evaluation by the RDQ will be compared with other established approaches to the diagnosis of gastroesophageal reflux disease (GERD) in a primary care patient population with symptoms thought to be of upper gastrointestinal (GI) tract origin.


Condition Intervention Phase
Gastroesophageal Reflux
 Drug: Esomeprazole
Procedure: Bravo technique
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Diagnostic
Official Title: A Single-Blind Single Arm Study to Validate the Reflux Disease Questionnaire (RDQ) for the Diagnosis of Reflux Disease in Primary Care in Patients Treated With Esomeprazole 40 mg o.d.

Resource links provided by NLM:

MedlinePlus related topics: GERD
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Selection of RDQ items (RDQ will be completed by subject at Screening and visit 4)
  • Presence/absence of GERD as assessed by endoscopic Los Angeles (LA) grade (gastroesophageal endoscopy will be performed at visit 2)
  • pH monitoring (% time with esophageal pH<4; Bravo pH-Monitoring will be performed from visit 2 to 3.1)
  • Symptom Associated Probability (outcome test for Bravo pH monitoring)
  • Outcome of PPI test (is assessed between visit 3.2 and 4.

Secondary Outcome Measures:
  • Mean item score for the GSRS dimensions at the initial and last visit (as assessed by answers of patient at visit 1 and visit 4)
  • RDQ item scores and RDQ mean item scores for RDQ dimensions at baseline and at the end of treatment (as assessed by answers of patient at Screening and visit 4)
  • Occurrence and severity of clinical symptoms at the initial and last visit (as reported by the subject)

Estimated Enrollment: 350
Study Start Date: September 2005
Study Completion Date: November 2006
  Eligibility

Ages Eligible for Study:   18 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who seek medical advice at their family doctor (primary care physician) for symptoms thought by the primary care physician to arise from the upper GI tract
  • The symptoms thought to pertain to the upper GI tract must have been present for at least 4 weeks prior to Visit 1 and to have occurred at least twice a week during that period
  • The symptoms thought to pertain to the upper GI tract must have been of at least mild severity for a minimum of 3 days during the week prior to Visit 1

Exclusion Criteria:

  • Upper GI endoscopy performed within a year prior to Visit 1
  • Previous anti-reflux surgery, surgery for peptic ulcer or any form of upper gastrointestinal resective surgery
  • Contra-indication to the Bravo™ procedure such as subjects with a history of bleeding diathesis, strictures anywhere along the GI-tract, esophageal varices, obstructions, or subjects equipped with a pacemaker, an implantable cardiac defibrillator or an implantable neurostimulator (NB: subjects with severe esophagitis (grade D) confirmed by endoscopy at Visit 2 can continue the study without performing the Bravo™ procedure)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00291746

Locations
Canada, Ontario
Research Site
Etobicoke, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
North York, Ontario, Canada
Canada, Quebec
Research Site
Mirabel, Quebec, Canada
Research Site
Pointe-Claire, Quebec, Canada
Research Site
Saint-Jerome, Quebec, Canada
Research Site
Saint-Leonard, Quebec, Canada
Denmark
Research Site
Glostrup, Denmark
Research Site
Herning, Denmark
Research Site
Odense, Denmark
Research Site
Randers, Denmark
Germany
Research Site
Berlin, Germany
Research Site
Bochum, Germany
Research Site
Dresden, Germany
Research Site
Garmisch-Partenkirchen, Germany
Research Site
Halle, Germany
Research Site
Magdeburg, Germany
Research Site
Mainz, Germany
Research Site
München, Germany
Research Site
Münster, Germany
Research Site
Siegen, Germany
Norway
Research Site
Bergen, Norway
Sweden
Research Site
Göteborg, Västra Götaland, Sweden
Research Site
Lund, Sweden
Research Site
Skövde, Sweden
Research Site
Stockholm, Sweden
United Kingdom
Research Site
Bicester, United Kingdom
Research Site
Coventry, United Kingdom
Research Site
London, United Kingdom
Research Site
West Bromwich, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Nexium Medical Science Director, MD AstraZeneca
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00291746     History of Changes
Other Study ID Numbers: D9914C00002, DIAMOND
Study First Received: February 14, 2006
Last Updated: March 11, 2009
Health Authority: Norway: Norwegian Medicines Agency

Keywords provided by AstraZeneca:
GERD

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Omeprazole
 Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 22, 2013